Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma

Ferroptosis is an iron-dependent cell death process that plays important regulatory roles in the occurrence and development of cancers, including hepatocellular carcinoma (HCC). Moreover, the molecular events surrounding aberrantly expressed long non-coding RNAs (lncRNAs) that drive HCC initiation and progression have attracted increasing attention. However, research on ferroptosis-related lncRNA prognostic signature in patients with HCC is still lacking. In this study, the association between differentially expressed lncRNAs and ferroptosis-related genes, in 374 HCC and 50 normal hepatic samples obtained from The Cancer Genome Atlas (TCGA), was evaluated using Pearson’s test, thereby identifying 24 ferroptosis-related differentially expressed lncRNAs. The least absolute shrinkage and selection operator (LASSO) algorithm and Cox regression model were used to construct and validate a prognostic risk score model from both TCGA training dataset and GEO testing dataset (GSE40144). A nine-lncRNA-based signature (CTD-2033A16.3, CTD-2116N20.1, CTD-2510F5.4, DDX11-AS1, LINC00942, LINC01224, LINC01231, LINC01508, and ZFPM2-AS1) was identified as the ferroptosis-related prognostic model for HCC, independent of multiple clinicopathological parameters. In addition, the HCC patients were divided into high-risk and low-risk groups according to the nine-lncRNA prognostic signature. The gene set enrichment analysis enrichment analysis revealed that the lncRNA-based signature might regulate the HCC immune microenvironment by interfering with tumor necrosis factor α/nuclear factor kappa-B, interleukin 2/signal transducers and activators of transcription 5, and cytokine/cytokine receptor signaling pathways. The infiltrating immune cell subtypes, such as resting memory CD4(+) T cells, follicular helper T cells, regulatory T cells, and M0 macrophages, were all significantly different between the high-risk group and the low-risk group as indicated in Spearman’s correlation analysis. Moreover, a substantial increase in the expression of B7H3 immune checkpoint molecule was found in the high-risk group. Our findings provided a promising insight into ferroptosis-related lncRNAs in HCC and a personalized prediction tool for prognosis and immune responses in patients.


INTRODUCTION
Hepatocellular carcinoma (HCC) is a heterogeneous tumor with increased incidence in the world (1,2). As a common malignancy, many factors have been proven to be involved in its development, such as virus infection and cirrhosis (3). Currently, the effective treatment options for HCC predominantly include percutaneous approaches, liver transplantation, hepatic resection, etc. (4,5). Even with advances in therapeutic management, the prognosis for patients with HCC remains unfavorable and poses a challenge to clinical therapists (6). Thus, uncovering novel and reliable screening methods is urgently needed to improve the diagnostic accuracy and therapeutic effect, facilitating the efforts to ameliorate the prognosis.
During the past few years, the literature suggested an increasing research progression in the area of tumor ferroptosis. Ferroptosis is a recently discovered form of reactive oxygen species (ROS)-mediated programmed cell death, which is dependent on iron metabolism and lipid peroxidation (7). The importance of ferroptosis has been demonstrated in the regulation of metabolism and redox biology, affecting the pathogenesis and treatment of cancers, including HCC. Shan and colleagues reported that ubiquitin-like modifier activating enzyme 1 promoted the development of HCC by upregulating the Nrf2 signaling pathway and downregulating Fe 2+ levels, triggering ferroptosis inhibitory bioactivities (8). Sorafenib and sulfasalazine could synergistically inhibit the activation of branched-chain amino acid aminotransferase 2, a key enzyme participating in sulfur amino acid metabolism, resulting in ferroptosis in HCC HepG2 cells in vitro and in vivo (9). In addition, Liu et al. reported a ferroptosis-and immune-related signature and found that this prognostic signature could be used to screen the HCC patients for immunotherapies and targeted therapies (10). Therefore, understanding the underlying mechanisms and functions of ferroptosis-associated gene changes in HCC is of vital importance.
Long non-coding RNAs (lncRNAs) are non-coding transcripts of 200 nucleotides in length, which could regulate the expression of various cancer-associated genes. Recently, Zhu et al. comprehensively investigated the molecular profiles of lncRNAs in plasma samples from HCC patients and revealed that the differentially expressed lncRNAs were mainly enriched in the biological functions related to tumorigenesis, such as cell metastasis, immune response, and metabolism regulation (11). A high level of LINC00958 aggravated HCC lipogenesis and progression through sponging miR-3619-5p, further upregulating the hepatoma-derived growth factor expression (12). To date, emerging evidence have shown the potential of lncRNAs in regulating ferroptotic cell death for cancer biology. In HCC cells, a high level of lncRNA GABPB1 antisense RNA 1 enhanced erastin-induced ferroptosis by blocking GA-binding protein subunit beta-1 (GABPB1) translation and suppressing peroxiredoxin-5 peroxidase, leading to inhibition of cellular antioxidant capacity and cell viability (13). However, the application of ferroptosis-lncRNA combinations in prognostic prediction for patients with HCC remains to be elucidated.
Here a promising prognostic model for HCC was developed based on ferroptosis-associated differentially expressed lncRNAs that could be used for prognosis prediction and selection of patients for immunotherapies.

Data Collection
Data from 424 samples, including 374 HCC tissues and 50 normal hepatic tissues, were downloaded from TCGA database up to April 1, 2021 (https://portal.gdc.cancer.gov/repository) as depicted in Figure 1A. The Data Transfer Tool of GDC Apps was utilized for downloading gene expression profiles and clinical information (https://tcga-data.nci.nih.gov/). The gene expression profiles were normalized using the scale method provided in the "limma" R package. Based on the set cutoff criteria of |fold-change| >2 and P <0.001, the differentially expressed genes (DEGs) between HCC and normal hepatic tissues were identified, and these included lncRNAs, proteincoding genes, miRNAs, etc. The lncRNA expression profiles and clinical information of another 59 tumor samples (GSE40144) were obtained from the GEO database (http://www.ncbi.nlm.nih. gov/geo) as testing cohort. The follow-up for the patients described in GSE40144 did not exceed 5 years.

Identification of Ferroptosis-Related lncRNAs
To identify ferroptosis-related lncRNAs, 60 ferroptosis-related genes were retrieved from the previous literature (Supplementary Table S1) (14), which contains an up-to-date list of ferroptosis-related genes. Pearson's test was performed to examine the correlation between ferroptosis-related DEGs and differentially expressed lncRNAs. Pearson's R >0.5 was considered to be statistically significant.

Cell Culture
The human embryonic hepatocyte-HHL-5-and HCC cells-MHCC97H and HUH-7-were cultured in Dulbecco's modified Eagle's medium, supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. The cultures were placed in a sterile incubator maintained at 37°C with 5% CO 2 . The cells in logarithmic growth phase were collected for subsequent experiments.

RNA Extraction and Quantitative PCR
Total cellular RNA was extracted using the TRIzol reagent (Invitrogen, 15596-026) according to the protocol of the manufacturer. The cDNA synthesis was reverse-transcribed using the PrimeScript RT reagent kit (Takara, 6210, China). The qPCR assay was conducted with iTaq Universal SYBR green Supermix (Bio-Rad, 172-5850, USA). The gene expression levels of candidate lncRNAs were normalized to 18srRNA expression levels. The relative quantification of lncRNAs was calculated using the 2-DDCT method (15)(16)(17). The sequences of all primers used in this study are provided in Supplementary Table S2.

Apoptosis Analysis
For apoptosis analysis, HUH-7 cells were transfected with the lncRNA-targeted siRNAs (GenePharma, China). The sequences of all siRNAs used in this study are provided in Supplementary  Table S2. Afterward, the cell apoptosis rate was analyzed using Annexin V-fluorescein isothiocyanate (BD Biosciences, USA). The Dxp AthenaTM flow cytometer (Cytek, Fremont, CA, USA) was used to analyze the results of the flow cytometry.

Colony Forming Assay
The HUH-7 cells were transfected with lncRNA-targeted siRNAs for about 48 h. Afterward, 1,000 cells were plated in six-well culture plates and cultured for about 15 days. The cellular colonies were counted by staining with crystal violet.

Lipid Peroxidation Assay
Lipid peroxidation was analyzed using a lipid peroxidation assay kit (Sigma, MAK085) according to the protocol of the manufacturer. Upon oxidative stress, one of the end products, such as malondialdehyde (MDA), could act as a promising marker for lipid peroxidation. Then, the reaction of MDA with thiobarbituric acid results in a pink color with a maximum absorption at 532 nm. Therefore, the levels of cellular lipid peroxidation can be identified by measuring the absorbance at 532 nm.

Iron Assay
The concentration of ferrous (Fe 2+ ) and/or ferric (Fe 3+ ) iron in biological samples could be determined using an iron assay kit (Abcam, ab83366). In brief, in the acid assay buffer, the ferric carrier proteins could dissociate ferric into the solution. Then, the reaction of free ferrous iron with Ferene S results in stablecolored complexes with absorbance at 593 nm. Therefore, the levels of intracellular iron can be identified by measuring the absorbance at 593 nm.

Construction and Validation of Ferroptosis-Related lncRNA Signature
Least absolute shrinkage and selection operator (LASSO) Cox regression of overall survival (OS) with a 10-fold cross-validation was performed to screen for ferroptosis-related lncRNAs with prognostic values. A total of 374 lncRNA-seq samples and the latest clinical follow-up information were downloaded from TCGA using GDC API (https://portal.gdc.cancer.gov/ repository). Patients with unknown clinical information were excluded (n = 92), leaving 255 lncRNA-seq samples in the final cohort for analysis. The R package "glmnet" was used to identify the gene signature that contains the most helpful biomarkers for prognosis, and the risk score of each sample in all the datasets was calculated based on the signature (18). For the training group, the lncRNA-based prognosis risk score was established by linearly combining the following formula with the expression levelmultiplied regression model (b): risk score = blncRNA1 × lncRNA1 expression + blncRNA2 × lncRNA2 expression + · ···· + blncRNAn × lncRNAn expression. To evaluate the predictive power of the lncRNA-based prognosis risk classifier, receiver operating characteristic (ROC) of 10-year survival was analyzed using the R package "timeROC" in the training and testing datasets (19). For survival analysis, the samples were divided into high-risk group and low-risk group based on the optimal cutoff value of risk score as analyzed by the R package "survival" (20). Kaplan-Meier analysis was used to explore the prognostic significance of the ferroptosis-associated nine-lncRNA signature on HCC. Next, univariate and multivariate Cox regression analyses were conducted to assess whether this risk score model displayed good predictive ability for prognosis independent of other clinicopathological features, such as body mass index, age, gender, and pathologic staging. In addition, a prognostic nomogram was established based on the TCGA-HCC dataset. All independent prognostic parameters and relevant clinical parameters were included in the construction of a prognostic nomogram via a stepwise Cox regression model to predict the 3-, 5-, and 10-year OS of HCC patients in the TCGA dataset. TCGA was normalized prior to the CIBERSORT analysis. The statistical significance of the deconvolution results was evaluated by a derived P-value (P < 0.05) to filter out the samples with less significant accuracy. The association between the risk score of the signature and immune cells was assessed using Spearman's correlation test. Pearson's test was used to assess the correlation between the risk score of the signature and the expression of the immune checkpoint genes, such as programmed cell death protein 1 (PD1), PD ligand 1 (PDL1), cytotoxic T-lymphocyte-associated protein 4 (CTLA4), V-set immunoregulatory receptor (VSIR) (22), and B7H3 (23).

Function Enrichment Analysis
Gene set enrichment analysis (GSEA) (24) was performed to identify the potential molecular mechanisms or potential functional pathways that involve the ferroptosis-related lncRNA signature. The TCGA samples were divided into a high-risk group and a low-risk group according to the optimal cutoff values. GSEA was performed in java GSEA v. 4

Statistical Analysis
All statistical analyses were performed using RStudio and its appropriate packages. P-values <0.05 were regarded as statistically significant.

Identification of Differentially Expressed Ferroptosis-Associated lncRNAs
We identified 3,714 genes (3,433 upregulated and 281 downregulated) that were differentially expressed in the TCGA-HCC dataset ( Figures 1A, B and Supplementary Table S3). Moreover, the pie chart exhibited that the differentially expressed lncRNAs (DE-lncRNAs) accounted for up to 32.70% of the DEGs (Supplementary Figure S1 and Supplementary  Table S4). Ferroptosis has been reported to be involved in the development of HCC (25,26), so we wanted to explore whether ferroptosis-related genes existed in the DEGs. As shown in the Venn diagram (http://bioinformatics.psb.ugent.be/webtools/ Venn/), seven ferroptosis-associated genes (ACSL4, FANCD2, G6PD, MT1G, NQO1, PTGS2, and SLC7A11) were identified among the 3,714 DEGs ( Figure 1C). A total of 24 DE-lncRNAs were determined as the ferroptosis-related lncRNAs ( Supplementary Table S5). Moreover, compared with normal hepatic tissues, 23 DE-lncRNAs were highly expressed in the HCC tissues, while only one DE-lncRNA (RP11-295M3.4) was lower in the HCC tissues (Supplementary Table S6). The heat map indicated a correlation between the 24 DE-lncRNAs and the seven ferroptosis-associated genes (R > 0.5, Figure 1D).  From the abovementioned 24 ferroptosis-associated lncRNAs, nine lncRNAs (CTD-2033A16.3, CTD-2116N20.1, CTD-2510F5.4, DDX11-AS1, LINC00942, LINC01224, LINC01231, LINC01508, and ZFPM2-AS1) were ultimately identified to be related to prognosis (Figures 2A, B and Supplementary Table S7). Kaplan-Meier survival analysis was further used to evaluate the significance of lncRNA expression on the prognosis of patients. As shown in Figures 2C-K Figure 2L). In addition, qPCR showed that the expression levels of the nine candidate lncRNAs were significantly increased in two HCC cell lines-MHCC97H and HUH-7-compared to the normal liver cell line, HHL-5 ( Figure 3A). Given that the roles of several lncRNAs, such as CTD-2033A16.3, LINC01231, and LINC01508, in HCC have not been reported, we wanted to explore whether these lncRNAs affect the apoptosis and proliferation of HCC cells. As expected, the knock-down of CTD-2033A16.3, LINC01231, and LINC01508 by siRNAs significantly promoted cell apoptosis and attenuated cell survival in the HCC cells HUH-7 ( Supplementary Figures S2A-E). In addition, studies have indicated that intracellular iron and MDA are the characteristic features of ferroptosis (27). Next, we wanted to assess how these candidate lncRNAs regulate the cellular iron and MDA. As shown in Figures 3B, C, the knock-down of CTD-2033A16.3, LINC01231, and LINC01508 by siRNAs significantly improved the concentration of cellular iron and MDA in the HCC cells HUH-7, indicating their anti-ferroptosis effects. The results suggest that these ferroptosis-associated lncRNAs play important roles in HCC pathology.
Subsequently, an X-tile diagram was used to produce the optimal cutoff point for the risk score. According to this cutoff value of risk score, the TCGA-HCC patients were divided into a high-risk group and a low-risk group. A prognostic curve and a scatter plot were used to indicate the risk score and the survival status of each HCC patient ( Figures 4A, B). Moreover, most of the death cases were mainly distributed in the high-risk group ( Figure 4B). In addition, the heat map of the expression profiles of candidate lncRNAs demonstrated that CTD-2033A16.3, CTD-2116N20.1, CTD-2510F5.4, DDX11-AS1, LINC00942, LINC01224, LINC01231, LINC01508, and ZFPM2-AS1 were all highly expressed in the high-risk group ( Figure 4C and Supplementary Table S9). Taken together, these findings presented the ferroptosis-associated nine-lncRNAs as the prognostic signature for HCC patients.

The Prognostic Value of Ferroptosis-Associated lncRNA Signature
Kaplan-Meier analysis validated that the HCC-TCGA patients in the high-risk group displayed a significantly worse survival than those in the low-risk group for the 3-, 5-, and 10-year survival times ( Figures 5A-C). Furthermore, the timedependent ROC analyses showed that the AUC of the risk score model was 0.812 at 3 years, 0.846 at 5 years, and 0.908 at 10 years ( Figures 5D-F). To demonstrate its prognostic generality, we further verified this nine-lncRNA-based risk score model with a GEO dataset (GSE40144), which contains lncRNA expression profiling and clinical survival data from 59 HCC patients. Consistent with the results from the HCC-TCGA cohort, the Kaplan-Meier curves revealed that the survival of HCC cases in the high-risk group was significantly lower than those in the low-risk group (Supplementary Figure S3A), and the AUC of a time-dependent ROC curve for the survival prediction of risk score model was 0.635 at 3 years (Supplementary Figure S3B). All these data demonstrated the superior specificity and sensitivity of this ferroptosis-associated nine-lncRNA signature than other clinical parameters. Next, univariate Cox analysis revealed that lncRNA-based signature (hazard ratio: 2.211, 95% confidence interval: 1.696-2.882) as well as T stage (hazard ratio: 1.483, 95% confidence interval: 1.919-1.847) were independent factors for the prognosis of HCC patients ( Figure 5G). The multivariate Cox analysis revealed likewise that both the lncRNA-based signature (hazard   Figure 5H). To make the lncRNA-based signature more applicable in the clinic, a nomogram was established to explore the probability of the lncRNA signature in predicting the 3-, 5-, and 10-year survival in the TCGA-HCC cohort. As shown in Figure 5I, the predictive factors in the nomogram contained the novel risk score model and other clinicopathological features. In this combined nomogram, the risk score model was proven to exert the most excellent weight among all these clinically relevant covariates, which was similar to the findings from the multivariable Cox regression analysis. These studies collectively verified that this novel ferroptosis-associated lncRNA signature could reliably serve as an independent prognostic factor for patients with HCC.

GSEA Enrichment and Immunity Analysis of the Risk Score
The GSEA analysis indicated that the tumor hallmarks correlated with the low-risk group, which may be involved in the regulation of several immune-associated signaling pathways, such as tumor necrosis factor a (TNFa)/nuclear factor kappa-B (NFkB), interleukin 2 (IL2)/signal transducers and activators of transcription 5 (STAT5), etc. (Figures 6A, B). Moreover, the GSEA analysis, along with the KEGG pathways, further revealed that the pathways correlated with the low-risk group were mainly involved in the regulation of cytokine/cytokine receptor signaling pathways ( Figure 6C). Previous studies reported that TNFa could promote NFkB activation through binding with TNF receptor, facilitating the production of elevated levels of T-helper 1/T-helper 17-related cytokines that drive proinflammatory signaling (28). Inhibition of the TNFa/ NFkB-driven proinflammatory signaling resulted in the suppression of tumor growth and progression in vivo and in vitro (29). In addition, IL2 and its downstream target STAT5 have been proven to exert an effect on multiple aspects of immune responses, for example, the regulation of T cell development and function (30,31). Thus, GSEA enrichment confirmed the biological significance of the ferroptosisassociated lncRNA signature in immune regulation.
To determine whether this nine-lncRNA signature was related to tumor immunity, we next evaluated the association between the risk score and the 22 types of TIICs in HCC from the CIBERSORT algorithm (Supplementary Figure S4). As shown in Figure 7A and Supplementary Table S10, the heat map of immune responses based on CIBERSORT displayed that M0 macrophages and T cell functions, including follicular helper T cells, regulatory T cells, and resting memory CD4(+) T cells, were all significantly different between the high-risk group and the low-risk group. We observed significantly higher proportions of resting memory CD4(+) T cell and lower proportions of follicular helper T cells, regulatory T cells, and M0 macrophages in the high-risk group (Figures 7B-E). These observations implied that the infiltration of these immune cell subtypes might exert an important influence on the prognosis of HCC patients. Given the clinical importance of therapeutic strategies based on immune checkpoint blockade in HCC (32,33), we then explore the association between the risk score and several immune checkpoints, such as PD1, PDL1, CTLA4, VSIR, and B7H3. As shown in Figure 7F, the heat map showed the positive relations between risk score and these immune checkpoints. Moreover, a substantial increase in the expression of B7H3 was found in the high-risk group ( Figure 7G). Taken together, these data suggested that the ferroptosis-associated lncRNA signature might affect the response to immunotherapy in HCC patients.

DISCUSSION
HCC is one of the most common malignancies with a high mortality in the world. Identifying reliable and effective biomarkers for HCC prognosis is of great importance. Here we identified a novel ferroptosis-related nine-lncRNA signature in a large-scale HCC cohort, including a testing dataset and a validation dataset, demonstrating its sensitivity and specificity.
In previous investigations, the lncRNA signatures for prognostic prediction have been described in many kinds of cancers, such as breast cancer (34), gastric cancer (35), etc. Similarly, based on the differentially expressed lncRNAs and disease pathogenesis, several lncRNA-associated signatures have also been developed to predict the outcome of HCC patients. A six-lncRNA signature (MSC-AS1, POLR2J4, EIF3J-AS1, SERHL, RMST, and PVT1) could be used to effectively predict the HCC recurrence risk (36). Another autophagy-related four-lncRNA signature (LUCAT1, AC099850.3, ZFPM2-AS1, and AC009005.1) has been developed to evaluate the autophagyrelated regulatory mechanisms of identified lncRNAs in HCC outcome (37). However, the ferroptosis-lncRNA interaction in the HCC prognostic model remains to be clarified. Here we report for the first time the ferroptosis-related lncRNA signature for prognosis and immune response of HCC populations, providing a promising strategy with an important clinical implication for guiding individual therapy and improving outcome prediction. In addition, the biological functions of candidate lncRNAs in the pathology of human cancers have been proven in several independent reports, for example, the high-level expression of CTD-2510F5.4 strengthened the malignant phenotype in gastric cancer (38). Knockdown of DDX11-AS1 significantly inhibited cell proliferation and migration in HCC in vitro and in vivo (39). LINC01224 silently repressed the HCC progression through sponging of microRNA-330-5p (40). To date, ferroptosis has been recognized as a form of regulated cell death (41), which displays functional roles in HCC tumorigenesis and immune regulation. A newly identified circular RNA, Circ0097009, could upregulate the expression of SLC7A11, a key ferroptosis-associated regulator, by sponging miR-1261 in multiple HCC cell lines (42). O-GlcNAcylationmediated YAP stabilization enhanced the sensitivity of HCC cells to RSL3-induced ferroptosis in vitro and in vivo (43). Recent studies have reported the direct crosstalk between ferroptosis and anti-tumor immunity. Tumor-infiltrating lymphocyte-mediated ferroptosis can effectively enhance the efficacy of immune checkpoint inhibitors. Iron overload in cancer cells is considered to boost the immune checkpoint blockade in HCC therapy via stimulating ROS accumulation and sensitizing cancer cells to ferroptosis (44,45). Thus, explorations focusing on the detailed mechanisms and functions of ferroptosis in HCC will help pave the way to identify ferroptosis induction as a promising therapeutic method.
Through strengthening the immune system of patients, immunotherapy has been shown to be successful in making cancer a curable disease in various malignancies. A considerable body of preclinical and clinical literatures highlight that immune-based therapeutic strategies offer survival benefits for HCC. Moreover, a combination of immunotherapy and other therapeutic methods is likely to become an alternative option in HCC treatment (46,47). Wen et al. synthetized a doublestranded polyinosinic-polycytidylic acid (polyIC) and demonstrated that the combination of polyIC with checkpoint inhibitors could distinctly activate the anti-tumor immune, thus effectively preventing liver tumorigenesis (48). In addition, emerging studies have proven the importance of tumorinfiltrating lymphocytes in driving immune evasion during HCC progression, including regulatory T cells, tumorassociated macrophages, etc. (49). The exhaustion of follicular helper T cells induced by intra-tumoral PDL1 resulted in the defective B cell function, facilitating the progression of advanced HCC (50). In this study, high levels of follicular helper T cells, regulatory T cells, and M0 macrophages were found in the highrisk group, indicating immune tolerance in the high-risk HCC patients. Thus, the ferroptosis-related lncRNA signature could provide potential cues for the patient selection for more effective anti-tumor immunotherapies. However, additional validation is required to understand the roles of our signature in the prediction of immunotherapeutic response in HCC patients.
However, there are several limitations in our study. Our report is mainly based on integrative bioinformatics, and effective experimental validation for these findings is currently lacking. Furthermore, the accuracy of ferroptosis-related lncRNA signature for the prognosis and immune regulation of HCC patients will remain an important issue in the clinic. In particular, the guidelines for the clinical use of this prognostic risk score model needs to be further defined.

CONCLUSION
In conclusion, a novel ferroptosis-related nine-lncRNA signature was constructed as an efficient computational technique for predicting the prognosis and immune response of patients with HCC. This signature was robustly connected to the risk scores, survival time, and tumor clinical parameters. Immune analysis supported the association between the risk value of this signature and specific immune cell populations. Thus, our findings suggested a promising insight into ferroptosis-related lncRNAs in the HCC population and provided a personalized prediction tool for prognosis and immune responses.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS
ZX, ZG, and YY contributed to the conception and design of the study. BP, QL, XC, YC, and SZ contributed to the writing, review, and/or revision of the manuscript. KG, XW, and QY provided administrative, technical, or material support. All authors contributed to the article and approved the submitted version.